Archive for the 'Invega' Category

25 Feb

Extended-Release Paliperidone (Invega): Kramer et al.

A study by Kramer and associates also evaluated the efficacy of paliperidone ER in a multiphase trial. In an eight-week run-in phase, 530 patients were hospitalized and received open-label paliperi-done. Dosing was flexible, starting at 9 mg once daily, and the dose could be adjusted between 3 and 15 mg once daily. The most commonly […]

24 Feb

Extended-Release Paliperidone (Invega): INDICATIONS

INDICATIONS Paliperidone was approved in December 2006 for the acute treatment of schizophrenia and for the long-term mainteĀ­nance treatment of schizophrenia in April 2007.

23 Feb

Extended-Release Paliperidone (Invega): CHEMICAL AND PHYSICAL PROPERTIES

The psychotropic agent paliperidone is chemically related to risperidone. This active metabolite belongs to the ben-zisoxazole derivative class and contains a racemic mixture of (+) and (-) enan-tiomers of paliperidone. It is available in strengths of 3, 6, or 9 mg.

22 Feb

Extended-Release Paliperidone (Invega)

INTRODUCTION Schizophrenia is a chronic mental illness that affects between 0.5% and 1% of the population in the U.S. today. Even though schizophrenic patients characteristically have psychoses, including hallucinations and delusions, this debilitating disease impairs their functional capacity to learn, work, care for themselves, maintain interpersonal relationships, and sustain general living skills. Forty percent to […]

© 2008 HIV/AIDS News & Information